Financials · SMTI

Sanara MedTech Inc. (SMTI) financials

For the twelve months ended Jun 30, 2026, Sanara MedTech Inc. reported $109.81M of revenue and -$32.02M of net income.

Revenue, TTM
$109.81M
Revenue growth, YoY
+13.0%
Net income, TTM
-$32.02M
Net margin
-29.2%
Free cash flow, TTM
$4.50M
EPS, diluted, TTM
-$3.72
Cash
$15.42M
Total debt
$46.48M
P/S
2.64
Market cap
$289.8M
Annual revenue$103.12M
FY2016FY2025
Annual net income-$37.56M
FY2016FY2025
Annual free cash flow$2.16M
FY2016FY2025

SMTI revenue and earnings growth

SMTI revenueQ2 2026$28.14M

Quarter YoY
+9.0%
QoQ
+1.2%
FY YoY
+19.0%
5Y CAGR
+45.9%
10Y CAGR
+40.8%

SMTI revenue was $28.14M in fiscal Q2 2026 (ended Jun 30, 2026), up 9.0% from a year earlier and up 1.2% from the prior quarter. For the full fiscal 2025 it was $103.12M, up 19.0% from fiscal 2024. Compound annual growth was +45.9% over 5 years and +40.8% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.

SMTI net incomeQ2 2026-$452.9K

SMTI net income was -$452.9K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.01M a year earlier. For the full fiscal 2025 it was -$37.56M, compared with -$9.66M in fiscal 2024.

SMTI EPSQ2 2026-$0.05

SMTI diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.23 a year earlier. For the full fiscal 2025 it was -$4.36, compared with -$1.14 in fiscal 2024.

SMTI free cash flowQ2 2026$2.03M

Quarter YoY
+125.2%

SMTI free cash flow was $2.03M in fiscal Q2 2026 (ended Jun 30, 2026), up 125.2% from a year earlier. For the full fiscal 2025 it was $2.16M, compared with -$229.6K in fiscal 2024. Fiscal 2025 is the highest of the 13 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$103.12M$86.67M$64.99M$45.84M$24.14M$15.59M$11.77M$5.84M$6.30M$5.51M
Cost of revenue$7.52M$8.14M$7.85M$6.36M$2.31M$1.62M$1.21M$507.4K$806.0K$943.6K
Gross profit$95.60M$78.53M$57.14M$39.48M$21.83M$13.97M$10.56M$5.33M$5.50M$4.56M
Research and development$5.07M$2.83M$4.13M$3.37M$558.7K$40.2K----
Selling, general and admin$78.72M$71.67M$56.99M$45.98M$28.05M$18.67M$13.07M$5.74M$5.28M$3.95M
Operating income$7.30M$1.26M-$4.22M-$12.52M-$7.38M-$5.03M-$2.74M-$501.9K$120.4K-$272.1K
Interest expense$6.76M$3.13M$475.8K$284.7K$711$11.5K$105.9K$86.6K$126.8K$174.5K
Pre-tax income-$393.1K-$1.89M-$4.44M-$13.94M-$7.99M-----
Income tax-$48.4K--$5.84M-$0$0$0$0$0
Net income-$37.56M-$9.66M-$4.30M-$7.94M-$7.92M-$4.45M-$2.81M-$600.6K$331.3K-$415.7K
EPS, basic-$4.36-$1.14-$0.52-$1.00-$1.08-$0.76-$1.32$0.00$0.00-$0.01
EPS, diluted-$4.36-$1.14-$0.52-$1.00-$1.08-$0.76-$1.32$0.00$0.00-$0.01
Diluted shares8.6M8.5M8.3M7.9M7.3M5.7M2.1M217.2M208.6M108.6M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$16.58M$15.88M$5.15M$8.96M$18.65M$455.4K$6.61M$176.4K$463.2K$833.5K
Receivables$12.00M--$6.81M$2.86M$0----
Inventory$3.95M$2.75M$4.72M$3.55M$2.05M$1.15M$746.5K$465.3K$711.4K$348.5K
Current assets$33.54M$33.31M$19.01M$20.62M$24.61M$4.48M$8.86M$1.69M$2.04M$2.00M
Goodwill$3.60M$3.60M$3.60M$3.60M------
Total assets$72.94M$88.09M$73.87M$61.04M$36.40M$9.83M$11.12M$1.71M$2.22M$2.17M
Current liabilities$18.63M$15.29M$13.77M$12.81M$6.02M$3.54M$2.64M$1.12M$2.12M$1.39M
Short-term debt--$580.4K---$0---
Long-term debt$45.97M$30.69M$9.11M--$0$1.50M$0$0$1.20M
Total debt$45.97M$30.69M$9.69M--$0$1.50M$0$0$1.20M
Total liabilities$67.01M$49.18M$29.28M$19.32M$6.24M$3.99M$4.72M$1.12M$2.12M$2.59M
Shareholders' equity$5.94M$38.91M$44.59M$41.72M$30.15M$5.84M$6.39M$586.8K$102.5K-$423.1K

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$6.79M-$23.8K-$3.25M-$5.55M-$4.81M-$4.03M-$2.17M$277.1K-$139.9K$409.2K
Capital expenditures$4.63M$205.8K$265.2K$147.0K$171.9K$544.4K$182.8K$8.5K$43.9K$3.0K
Free cash flow$2.16M-$229.6K-$3.51M-$5.70M-$4.99M-$4.58M-$2.35M$268.7K-$183.8K$406.2K
Investing cash flow-$14.97M-$6.61M-$10.21M-$3.51M-$5.28M-$2.74M-$1.20M-$8.5K-$85.9K-$3.0K
Financing cash flow$8.89M$17.37M$9.64M-$627.3K$28.30M$622.3K$9.80M$0-$144.6K$244.9K
Stock-based compensation$5.15M$4.44M$3.44M$2.70M$2.67M$1.40M$0---
Depreciation and amortization$3.95M$4.92M$3.68M$2.37M$597.0K$291.4K$120.0K$83.9K$80.6K$60.9K

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY19.0%33.4%41.8%89.9%54.9%32.5%101.6%-7.4%14.5%63.3%
Gross margin92.7%90.6%87.9%86.1%90.4%89.6%89.7%91.3%87.2%82.9%
Operating margin7.1%1.5%-6.5%-27.3%-30.6%-32.3%-23.3%-8.6%1.9%-4.9%
Net margin-36.4%-11.2%-6.6%-17.3%-32.8%-28.5%-23.9%-10.3%5.3%-7.5%
Free cash flow margin2.1%-0.3%-5.4%-12.4%-20.7%-29.4%-20.0%4.6%-2.9%7.4%
Return on equity-632.5%-24.8%-9.7%-19.0%-26.3%-76.1%-44.0%-102.3%323.1%-
Return on assets-51.5%-11.0%-5.8%-13.0%-21.8%-45.2%-25.3%-35.1%14.9%-19.1%
Current ratio1.802.181.381.614.091.273.351.510.961.43
Debt to equity7.740.790.22--0.000.230.000.00-

Source: XBRL data Sanara MedTech Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

SMTI peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
SMTI$109.81M+13.0%-$32.02M-29.2%$289.8M
ISRG$11.58B+20.5%$2.96B25.5%$156.96B
EW$6.67B+13.4%$1.02B15.3%$58.73B
STE$6.17B+8.1%$826.90M13.4%$24.60B
ZBH$8.57B+7.0%$767.30M9.0%$19.98B
MAS$7.67B+0.9%$926.00M12.1%$15.85B
SNN$6.16B+6.1%$625.00M10.1%$13.04B
ALGN$4.16B+4.4%$491.87M11.8%$11.70B
AIT$5.06B+8.5%$424.12M8.4%$10.35B

SMTI FAQ

9 questions
  • What is SMTI revenue?
    Sanara MedTech Inc. (SMTI) reported $109.81M of revenue for the twelve months ended Jun 30, 2026. That is up 13.0% from the year before. Revenue for fiscal 2025 was $103.12M.
  • Is SMTI profitable?
    No. Sanara MedTech Inc. reported a net loss of $32.02M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does SMTI have?
    Sanara MedTech Inc. reported $15.42M in cash and cash equivalents and $46.48M of debt on its most recent balance sheet in SEC filings.
  • How fast is SMTI revenue growing?
    Sanara MedTech Inc.'s revenue changed +19.0% in fiscal 2025, to $103.12M. Its compound annual growth rate was +45.9% over 5 years and +40.8% over 10 years.
  • What is SMTI gross margin?
    Sanara MedTech Inc.'s gross profit was $102.16M on $109.81M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 93.0%.
  • What is SMTI free cash flow?
    Sanara MedTech Inc. generated $4.50M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of $5.69M less capital expenditures.
  • What is SMTI earnings per share?
    Diluted earnings per share were -$3.72 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did SMTI last report financial results?
    The latest statements here come from Sanara MedTech Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this SMTI financial data come from?
    Quantisnow builds these statements from the structured XBRL data Sanara MedTech Inc. files with the SEC. It is provided for information only and is not investment advice.